Mounjaro for Prediabetes: What the Clinical Evidence Shows

What SURMOUNT-1 found, and what it doesn't settle

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight plus at least one weight-related condition. Participants did not have type 2 diabetes, but a meaningful subset had prediabetes at enrolment. By week 72, the majority of those individuals showed fasting glucose and HbA1c values that had normalised, a finding that held across the 5mg, 10mg and 15mg doses, with the effect most pronounced at higher doses. Average body-weight reduction reached roughly 20–21% at 15mg. The glucose result is biologically coherent: tirzepatide activates both GIP and GLP-1 receptors, which together influence insulin secretion, insulin sensitivity and gastric emptying. Less weight, slower glucose absorption, and better insulin response all push in the same direction for someone whose blood sugar sits in the prediabetic range.

What the trial doesn't tell us is whether tirzepatide should be prescribed because of prediabetes in the absence of obesity. The licensed indication for weight management requires a BMI of at least 30, or at least 27 with a weight-related condition. Prediabetes is widely accepted as a qualifying weight-related condition in that second category, but the prescriber's job is to weigh your whole picture, not just one number. NICE's appraisal of tirzepatide, TA1026, does not address prediabetes as a standalone indication; it recommends tirzepatide for adults with a BMI of at least 35 and one or more weight-related comorbidities on the NHS pathway, with lower BMI thresholds for some ethnic backgrounds.

The honest summary: the glucose data are encouraging and scientifically credible, but prediabetes alone does not automatically mean tirzepatide is the right or only option. That conversation belongs with a clinician.

Where prediabetes sits within Mounjaro's licensed weight-management criteria

Mounjaro's UK weight-management licence, granted by the MHRA, applies to adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition. Prediabetes (diagnosed by an HbA1c between 42 and 47 mmol/mol or a fasting glucose between 6.1 and 6.9 mmol/L) is consistently categorised in clinical practice as a metabolic comorbidity linked to excess weight. The NHS tirzepatide medicines page confirms the licensed weight-management indications clearly.

So for someone with a BMI of 28 and a confirmed prediabetes diagnosis, the weight-management licence is potentially in play. For someone with prediabetes and a BMI of 32, it almost certainly is. BMI alone never clinches approval, though; a prescriber reviews the full history, including liver function, kidney function, any history of pancreatitis, current medications, and cardiovascular risk. That review is the mechanism that makes a prescription safe, not just legal.

Separately, Mounjaro also holds a UK licence for diabetes, covering its approved use beyond weight management. If your blood sugar has already crossed the diagnostic threshold for type 2 diabetes, that changes the clinical conversation considerably. You can read more about how Mounjaro is used specifically in type 2 diabetes on a dedicated page, though the route to treatment is the same: a clinical assessment first.

What remains uncertain, and what that means practically

No long-term randomised trial has yet measured tirzepatide prescribed specifically to prevent progression from prediabetes to type 2 diabetes as its primary endpoint. The glucose findings from SURMOUNT-1 are secondary analyses, rigorous ones, from a well-designed trial, but not a dedicated prevention study. The MHRA has not issued a specific prediabetes indication for tirzepatide, and the MHRA Drug Safety Update communications to date address GLP-1 side-effect monitoring rather than prediabetes-specific prescribing guidance.

What that means practically: a prescriber considering Mounjaro for someone with prediabetes is making a clinical judgement supported by real mechanistic and trial evidence, but in the absence of a dedicated licence for that indication. Some GPs will engage with this; others will want to wait for longer-term data or refer to a specialist. Either response is clinically defensible.

One thing worth knowing: the treatment itself, if prescribed, is the same, a once-weekly subcutaneous injection using the Mounjaro KwikPen, starting at 2.5mg and titrated by the prescriber in four-week steps. If you're curious about what that looks like day-to-day, the pen arrives via DPD the next working day in plain, unbranded packaging, easy to store in the fridge door. The clinical process doesn't look different because of a prediabetes diagnosis; what differs is whether and why a prescriber decides it's the right option for you.

If you have concerns about alcohol and blood-sugar control alongside Mounjaro, our guidance on drinking alcohol while taking Mounjaro covers that topic. For a broader view of the treatment itself, our Mounjaro overview is the natural starting point.

Who to talk to, and what to expect from that conversation

Your GP is the right first port of call if you have a confirmed prediabetes diagnosis and want to explore whether Mounjaro is suitable. They can review your full metabolic picture, your weight trajectory, and any other conditions, and they hold your prescribing history. If your GP isn't familiar with tirzepatide in this context, or you'd rather not wait, a private route through a regulated online pharmacy is a legitimate alternative, provided clinical assessment is front and centre. It is also worth reading up on how Mounjaro is used for type 2 diabetes, since understanding where the prediabetes conversation ends and the diabetes conversation begins can help you arrive at that appointment better prepared.

At nume (at who we are) every consultation is personally read the same day by a GPhC-registered Independent Prescriber. Not software; a real clinician. If you'd find it helpful to understand the cost picture before starting, our Mounjaro pricing page sets out what a private prescription typically involves. And if questions arise after you start treatment, our aftercare team is available seven days a week, you can always get in touch.

If suitability is confirmed, start your free consultation, it takes a few minutes and is reviewed the same working day.